• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination.

作者信息

Valsecchi Carla, Gualtierotti Roberta, Arcudi Sara, Ciavarella Alessandro, Schiavone Lucia, Novembrino Cristina, Siboni Simona Maria, Mannucci Pier Mannuccio, Peyvandi Flora

机构信息

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.

Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy.

出版信息

Blood Adv. 2023 Jan 10;7(1):174-177. doi: 10.1182/bloodadvances.2022008989.

DOI:10.1182/bloodadvances.2022008989
PMID:36306338
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9635221/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bc8/9811197/4478b6f4f201/BLOODA_ADV-2022-008989-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bc8/9811197/288f687a5752/BLOODA_ADV-2022-008989-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bc8/9811197/09ddd06fbf10/BLOODA_ADV-2022-008989-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bc8/9811197/4478b6f4f201/BLOODA_ADV-2022-008989-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bc8/9811197/288f687a5752/BLOODA_ADV-2022-008989-fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bc8/9811197/09ddd06fbf10/BLOODA_ADV-2022-008989-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0bc8/9811197/4478b6f4f201/BLOODA_ADV-2022-008989-gr2.jpg

相似文献

1
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination.BNT162b2新型冠状病毒疫苗接种后，抗FVIII PEG抗体导致FVIII回收率降低。
Blood Adv. 2023 Jan 10;7(1):174-177. doi: 10.1182/bloodadvances.2022008989.
2
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率：哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
3
Kinetics of the humoral response 1-year following vaccination with BNT162b2 SARS-CoV-2 vaccine among maintenance hemodialysis patients.维持性血液透析患者接种BNT162b2新冠疫苗1年后的体液免疫反应动力学
J Nephrol. 2023 Jan;36(1):213-216. doi: 10.1007/s40620-022-01377-y. Epub 2022 Jul 9.
4
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.BNT162b2 和 CoronaVac 新冠疫苗对奥密克戎 BA.2 亚谱系引起的 SARS-CoV-2 无症状和有症状感染的有效性：一项前瞻性队列研究。
Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12.
5
Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection.科兴和国药疫苗及未感染过 SARS-CoV-2 医护人员与已感染过 SARS-CoV-2 医护人员接种后中和抗体滴度比较。
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taac010.
6
Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.接种 2 剂 BNT162b2 mRNA 疫苗后与抗 SARS-CoV-2 抗体水平相关的人口统计学和临床因素。
JAMA Netw Open. 2022 May 2;5(5):e2212996. doi: 10.1001/jamanetworkopen.2022.12996.
7
Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.血液透析患者中 BNT162b2 和 mRNA-1273 SARS-CoV-2 疫苗的真实世界有效性和免疫原性。
J Am Soc Nephrol. 2022 Jan;33(1):49-57. doi: 10.1681/ASN.2021060778. Epub 2021 Nov 17.
8
Association between a low response to rubella vaccination and reduced anti-severe acute respiratory syndrome coronavirus 2 immune response after vaccination with BNT162b2: a cross-sectional study.接种 BNT162b2 后风疹疫苗低应答与抗严重急性呼吸综合征冠状病毒 2 免疫应答降低的相关性：一项横断面研究。
Clin Microbiol Infect. 2023 Feb;29(2):253.e1-253.e5. doi: 10.1016/j.cmi.2022.09.007. Epub 2022 Sep 20.
9
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.辉瑞-BioNTech 新冠疫苗接种 6 个月后针对 SARS-CoV-2 关注变异株的抗体反应
Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9.
10
Humoral immune response after different SARS-CoV-2 vaccination regimens.不同 SARS-CoV-2 疫苗接种方案后的体液免疫应答。
BMC Med. 2022 Jan 21;20(1):31. doi: 10.1186/s12916-021-02231-x.

引用本文的文献

1
Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.在先前接受过治疗的重度先天性 A 型血友病患者中，rurioctocog alfa pegol 的免疫原性特征。
Blood Adv. 2024 Jun 11;8(11):2726-2739. doi: 10.1182/bloodadvances.2023011780.
2
DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond.用于疫情防范的DNA疫苗：新冠病毒及其他。
Vaccines (Basel). 2023 May 23;11(6):1016. doi: 10.3390/vaccines11061016.
3
Studying how administration route and dose regulates antibody generation against LNPs for mRNA delivery with single-particle resolution.

本文引用的文献

1
The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.N8-GP（培古洛单抗）治疗既往未治疗的儿童血友病 A 患者的安全性和疗效。
Blood Adv. 2023 Feb 28;7(4):620-629. doi: 10.1182/bloodadvances.2022007529.
2
Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine.SARS-CoV-2脂质纳米颗粒mRNA疫苗可增强人体中的抗聚乙二醇抗体。
ACS Nano. 2022 Aug 23;16(8):11769-11780. doi: 10.1021/acsnano.2c04543. Epub 2022 Jun 27.
3
Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice.
以单颗粒分辨率研究给药途径和剂量如何调节针对用于mRNA递送的脂质纳米颗粒的抗体产生。
Mol Ther Methods Clin Dev. 2023 May 11;29:450-459. doi: 10.1016/j.omtm.2023.05.008. eCollection 2023 Jun 8.
抗聚乙二醇抗体亲和力对聚乙二醇化促红细胞生成素β在小鼠体内加速血液清除的影响。
Biomed Pharmacother. 2022 Feb;146:112502. doi: 10.1016/j.biopha.2021.112502. Epub 2021 Dec 7.
4
Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies.聚乙二醇免疫原性：抗聚乙二醇抗体的理论、临床和实际问题。
ACS Nano. 2021 Sep 28;15(9):14022-14048. doi: 10.1021/acsnano.1c05922. Epub 2021 Sep 1.
5
An update of the current pharmacotherapeutic armamentarium for hemophilia A.血友病 A 的当前药物治疗武器库的更新。
Expert Opin Pharmacother. 2022 Jan;23(1):129-138. doi: 10.1080/14656566.2021.1961742. Epub 2021 Aug 18.
6
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.mRNA-脂质纳米颗粒 COVID-19 疫苗：结构与稳定性。
Int J Pharm. 2021 May 15;601:120586. doi: 10.1016/j.ijpharm.2021.120586. Epub 2021 Apr 9.
7
Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies.预先存在的和治疗诱导的抗聚乙二醇抗体的临床相关性
Regen Eng Transl Med. 2022;8(1):32-42. doi: 10.1007/s40883-021-00198-y. Epub 2021 Mar 25.
8
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.预先存在的针对聚乙二醇的抗体可降低儿童急性淋巴细胞白血病患者首次接受聚乙二醇化大肠杆菌天冬酰胺酶治疗时的天冬酰胺酶活性。
Haematologica. 2022 Jan 1;107(1):49-57. doi: 10.3324/haematol.2020.258525.
9
Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.N8-GP 治疗既往接受治疗的成人和青少年血友病 A 的长期安全性和疗效：pathfinder2 的最终结果。
J Thromb Haemost. 2020 Sep;18 Suppl 1(Suppl 1):5-14. doi: 10.1111/jth.14959.
10
Hemophilia therapy: the future has begun.血友病治疗：未来已来。
Haematologica. 2020 Mar;105(3):545-553. doi: 10.3324/haematol.2019.232132. Epub 2020 Feb 14.